Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M(1) receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

BACKGROUND: The cholinergic system and M(1) receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M(1) receptor partial agonist HTL0018318 is under development for the symptomatic treatment of Dementia’s including Alzheimer’s disease (AD) and dementia...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakker, Charlotte, Tasker, Tim, Liptrot, Jan, Hart, Ellen P., Klaassen, Erica S., Doll, Robert Jan, Brown, Giles A., Brown, Alastair, Congreve, Miles, Weir, Malcolm, Marshall, Fiona H., Cross, David M., Groeneveld, Geert Jan, Nathan, Pradeep J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061066/
https://www.ncbi.nlm.nih.gov/pubmed/33883008
http://dx.doi.org/10.1186/s13195-021-00816-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061066/
https://www.ncbi.nlm.nih.gov/pubmed/33883008
http://dx.doi.org/10.1186/s13195-021-00816-5

Ejemplares similares